Artelo Biosciences Inc. (ARTL)
1.06
0.03 (2.91%)
At close: Mar 05, 2025, 2:04 PM
Artelo Biosciences Income Statement
Year | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 |
Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Gross Profit | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Income | -10.29M | -7.44M | -4.69M | -3.21M | -2.34M | -232.79K | -29.69K | -15.24K | -15.27K |
Interest Income | 2K | 2K | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Pretax Income | -10.08M | -7.44M | -4.65M | -2.17M | -2.34M | -234.89K | -29.69K | -15.24K | -15.27K |
Net Income | -9.87M | -7.44M | -4.65M | -2.17M | -2.34M | -234.89K | -29.69K | -15.24K | -15.27K |
Selling & General & Admin | 5.96M | 4.6M | 2.77M | 2.12M | 1.09M | 232.79K | 29.69K | 15.24K | 15.27K |
Research & Development | 4.32M | 2.84M | 1.92M | 1.09M | 1.25M | n/a | n/a | n/a | n/a |
Other Expenses | n/a | n/a | 1.41K | 31.26K | 290.00 | 3.33K | n/a | n/a | n/a |
Operating Expenses | 10.29M | 7.44M | 4.69M | 3.21M | 2.34M | 232.79K | 29.69K | 15.24K | 15.27K |
Interest Expense | 5K | n/a | n/a | n/a | n/a | 2.1K | n/a | n/a | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 10.29M | 7.44M | 4.69M | 3.21M | 2.34M | 232.79K | 29.69K | 15.24K | 15.27K |
Income Tax | -209K | -4K | -60.41K | -2.04M | 8.00 | n/a | n/a | n/a | n/a |
Shares Outstanding (Basic) | 2.83M | 1.25M | 247K | 144K | 84K | 72K | 63K | 63.67K | 25K |
Shares Outstanding (Diluted) | 2.83M | 1.25M | 247.18K | 144.83K | 85.17K | 72.77K | 63.67K | 63.67K | 25.62K |
EPS (Basic) | -3.49 | -5.97 | -18.83 | -15 | -27.52 | -3.23 | -0.47 | -0.24 | -0.6 |
EPS (Diluted) | -3.49 | -5.97 | -18.83 | -15 | -27.52 | -3.23 | -0.47 | -0.24 | -0.6 |
EBITDA | -10.29M | -7.44M | -4.71M | -4.22M | -2.34M | -232.79K | -29.69K | -15.24K | -15.27K |
Depreciation & Amortization | 2K | -2K | 500.00 | 510.00 | 282.00 | 600.00 | 22.82K | n/a | n/a |